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In this issue of the JCI, Wang, Clemens, and colleagues demonstrate that 
hypoxia-inducible factor α (HIFα) signaling in bone-building osteoblasts is 
central to the coupling of angiogenesis and long bone development in mice 
(see the related article beginning on page 1616). They show that bone for-
mation controlled by osteoblast HIFα signaling is not cell autonomous but 
is coupled to skeletal angiogenesis dependent upon VEGF signaling. Thus, 
strategies that promote HIFα signaling in osteoblasts may augment bone 
formation and accelerate fracture repair.
Tremendous unmet clinical needs exist in 
musculoskeletal medicine. The direct costs 
of musculoskeletal diseases in the Unites 
States are well over $100 billion per annum 
(1). Osteoporosis and osteoarthritis are rec-
ognized as common and clinically impor-
tant, but other serious skeletal diseases also 
afflict our populace. In the setting of type 2 
diabetes mellitus (T2DM), lower-extremity 
musculoskeletal disease is prevalent, costly, 
and exceedingly difficult to manage, with 
fracture, arthropathy, ischemia, ulcer, and 
infection commonly confronting patients 
and clinicians. The total costs associ-
ated with lower-extremity amputation in 
T2DM alone are greater than the combined 
costs of treating fatal and nonfatal myo-
cardial infarction associated with T2DM 
(2). Stage-specific and disease-specific 
strategies are necessary to safely promote 
bone formation in individuals with: (a) 
underlying vasculopathies, such as those 
associated with diabetes or renal failure; 
(b) underlying malignancy of any sort; (c) 
extant osteoporosis that has removed tra-
becular templates for bone apposition; (d) 
osteoporosis in the setting of childhood 
growth and open epiphyses; and (e) drug- 
or coagulopathy-related disorders that 
cause avascular necrosis.
In this issue of the JCI, the study by Wang 
et al. (3) affords us a better understanding 
of the mechanisms coupling bone and vas-
cular physiology, providing insights use-
ful for devising novel strategies to address 
the mounting unmet needs in orthope-
dic medicine. The vasculature provides: 
(a) a sustentacular niche and source of 
adult mesenchymal stem cells, including 
osteoprogenitors; (b) the organizational 
and rate-limiting “point of reference” for 
Haversian bone formation; and (c) the 
conduit for calcium, phosphate, hemato-
poietic, and nutrient supply necessary for 
mineralization and calcium mobilization 
(4–11). We know precious little about how 
the vasculature integrates and conveys sig-
nals during skeletogenesis. However, VEGF 
(9) has emerged as the prototypic osteo-
genic-angiogenic coupling factor (10). The 
VEGF gene encodes a secreted polypeptide 
globally required for vasculogenesis and 
angiogenesis (11). Bioactivity is modulated 
by VEGF gene expression — and differen-
tial splicing that generates three unique 
gene products — with signals transduced 
via specific VEGF receptor tyrosine kinases 
(9). The name “VEGF” belies its contribu-
tions to osteoblast ontogeny, chondrocyte 
physiology, and osteoclast formation (10). 
VEGF signaling is tightly regulated in bone, 
coupled to morphogenetic, metabolic, 
inflammatory, and mechanical cues that 
control mineral metabolism. In addition 
to regulating the expansion and survival 
of mesenchymal progenitors (Figure 1 and 
below), signals provided by VEGFR2 medi-
ate angiogenic cross-talk with TNF recep-
tor 2 (TNFR2) (12), critical for postnatal 
defense against limb ischemia (13). Given 
the contributions of bone-vascular inter-
actions to all aspects of bone biology, our 
limited understanding of this important 
physiology impedes development of novel 
bone anabolic therapies.
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In their current study, Wang, Clemens, and 
colleagues (3) significantly advance our 
understanding of bone-vascular coupling 
by establishing the critical role for osteo-
blast hypoxia-inducible factor 1α (HIF-1α) 
and HIF-2α in bone formation (Figure 1). 
As recently reviewed (14), HIFs are com-
ponents of heterodimeric, hypoxia-acti-
vated transcription factor complexes that 
bind to well-characterized DNA cognates 
called hypoxia-response elements, activat-
ing the expression of genes such as VEGF 
and erythropoietin that can improve tissue 
oxygen delivery (15). Dependent upon cel-
lular context, HIF-1α and HIF-2α may or 
may not exhibit functional redundancy 
(14). The Clemens group first showed that 
osteoblasts express all necessary compo-
nents of the oxygen-sensing pathway in 
addition to HIF-1α and HIF-2α (herein 
collectively referred to as HIFα). These 
components include the oxygen-depen-
dent prolyl hydroxylases (PHDs) that “tag” 
HIFα for recognition by the E3 ubiquitin 
ligase von Hippel–Lindau protein (pVHL) 
and pVHL itself, necessary for HIFα pro-
teosomal degradation (3) (Figure 1). More-
over, the authors demonstrate hypoxia-
dependent nuclear accumulation of HIFα 
and concomitant upregulation of VEGF 
expression, indicating intact oxygen-sens-
ing functions in osteoblasts. To evaluate 
the biological importance of osteoblast 
HIF signaling in vivo, the authors used 
Cre-lox technology; they implemented the 
bone-specific human osteocalcin promoter 
as a delivery module for Cre recombinase 
expression in mice possessing floxed Vhl 
Nonstandard abbreviations used: BMP, bone mor-
phogenetic protein; BV/TV, bone volume/tissue vol-
ume; HIF, hypoxia-inducible factor; ΔHif1a mice, mice 
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alleles. This strategy abrogates pVHL accu-
mulation in mature osteoblasts (3). In this 
conditional knockout, denoted ΔVhl, osteo-
blast accumulation of both HIF-1α and 
HIF-2α was induced due to the absence 
of pVHL-dependent degradation (Figure 
1). The in vivo effects on long bone forma-
tion were remarkable; bone volume/tissue 
volume (BV/TV) increased by 70% with 
osteoblast-specific induction of HIFα sub-
units. Detailed histomorphometry revealed 
very early postnatal increases in trabecular 
osteoblast numbers during long bone mod-
eling — numbers that “normalized” once 
a new steady state of high bone mass was 
achieved in ΔVhl mice (3). In culture, osteo-
blasts possessing floxed Vhl alleles also 
upregulated HIFα when transduced with 
an adenoviral Cre vector — with concomi-
tant induction of VEGF. HIFα induction 
did not alter cultured osteoblast prolifera-
tion rate, apoptotic rate, matrix synthetic 
activity, or mineral deposition ex vivo; thus, 
the bone anabolic actions of osteoblast 
HIFα induction observed in vivo were not 
cell autonomous. Bone histomorphom-
etry and serum biochemistries showed no 
decrements in bone-resorbing osteoclast 
numbers or activity, excluding overt con-
tributions of osteoclast insufficiency to 
increased BV/TV in ΔVhl mice. However, a 
profound increase in bone vascularity was 
observed for the ΔVhl mice (3). Moreover, a 
massive increase in capillary sprouting was 
exhibited by ΔVhl long bones maintained 
in organ culture (3). Angiogenic responses 
were dependent upon paracrine VEGF 
actions, since: (a) VEGF-neutralizing anti-
body abrogated sprouting; and (b) skeletal 
production of VEGF mRNA was increased 
in ΔVhl mice without changes in circulating 
VEGF. Relationships to HIFα-dependent 
angiogenesis and bone formation were fur-
ther confirmed using mice in which Hif1a 
was conditionally knocked out in osteo-
blasts (ΔHif1a mice). Bone volume and vas-
cularity were reduced in ΔHif1a mice, with 
reductions partially offset by compensatory 
HIF-2α expression. The overlapping redun-
dancy of the latter was diligently demon-
strated using a third mouse model, Vhl gene 
deletion in ΔHif1a mice; these ΔVhl/ΔHif1a 
mice exhibited markedly increased HIF-2α 
protein accumulation, with concomitant 
restoration of bone volume and angio-
genesis (3). Thus, the authors conclude 
that osteoblast HIFα signaling is a central 
component of rate-limiting, osteogenic-
angiogenic coupling that controls long 
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mechanisms that are not cell autonomous 
and that utilize paracrine VEGF angiogenic 
signals to expand osteoblast numbers dur-
ing long bone development (3).
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How, then, might the angiogenic response 
and osteogenic-angiogenic coupling 
increase osteoblast numbers and pro-
vide the massive marrow bone formation 
observed (3)? Recently, several groups have 
identified the microvascular smooth mus-
cle cell, the pericyte, as an important osteo-
progenitor (16–24) (Figure 1). Demer, Can-
field, and colleagues have shown that the 
pericyte exhibits multipotentiality, capable 
of osteogenic, chondrogenic, adipogenic, 
and SMC differentiation (17, 18). Molecu-
larly, pericytes express early features of the 
VSMC lineage, including smooth muscle 
22 kDa (SM22), α-SMC, and species-spe-
cific gangliosides demarcated by the 3G5 
monoclonal antibody (17, 19). Anatomi-
cally, the pericyte is intimately juxtaposed 
to the endothelial capillary network. In the 
marrow microenvironment, the bone mar-
row stromal cell exhibits the histoanatomic 
characteristics of the pericyte (16). Thus, 
from this perspective the bone marrow 
stromal cell — the osteoprogenitor — can 
be viewed as a tissue-specific pericyte.
What is the ontogeny of the vascular 
pericyte? Cossu and colleagues provide 
data suggesting that the mesoangioblast 
(20), a vessel-associated mesenchymal 
stem cell with the capacity to differenti-
ate into cells of endothelial and VSMC 
lineages, might be the source of pericytes. 
Studies of differentiating murine ES cells 
confirm the existence of a highly plastic, 
VEGFR2+ endothelial-SMC progenitor — 
a mesenchymal stem cell that can give rise 
to mineralizing osteoblasts in culture via 
pericytic SMC lineage (23). Skeletal osteo-
blasts can and do arise from the pericyte 
cell lineage in vivo; SM22-positive and 
α-SMC–positive cells “coregister” with 
preosteoblasts identified using Col3.6-
GFP reporter mice following induction 
of de novo osteogenesis (24). Thus, con-
comitant with angiogenic sprouting, 
VEGF/VEGFR2 signaling is posited to 
expand the potential osteoprogenitor 
pool via the pericyte intermediate (Figure 
1). However, until better pericyte lineage 
markers are developed, or the effects of 
HIFα expansion are tested in the lineage 
reporter mice (24), the mechanisms pro-
posed remain speculative.
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Remarkably, unlike in long bone, little if 
any in vivo effect of osteoblast Vhl deletion 
was observed by Wang et al. in calvarial 
bone (3). Why might this occur? Unique 
and differentially regulated ontogeny and 
angiogenic responses likely contribute (25). 
There are places in the skeleton (e.g., neural 
crest–derived calvarial bone, lateral com-
ponents of the clavicle, the mid-diaphyseal 
collar of long bone) where bone forms via 
nonendochondral mechanisms (11, 25). 
Denoted as intramembranous ossifica-
tion, this osteoblast-mediated mineral 
deposition occurs directly in the type I col-
lagen–based extracellular matrix — without 
replacement of a precedent, avascular carti-
laginous template by bone and marrow as 
is required for endochondral ossification 
(10, 25). In the developing skull, it is prob-
able that cranial suture and dural mechani-
cal tension organize angiogenesis necessary 
for intramembranous ossification (26–28). 
VEGF expression in osteoblasts is mechan-
ically very responsive (29). Distraction 
osteogenesis — an orthopedic mechanical 
manipulation that promotes robust angio-
genesis and bone formation via nonendo-
chondral mechanisms — upregulates both 
HIF-1α and VEGF (29). Thus, it is tempting 
to speculate that the differences observed 
by Wang et al. (3) arise due to differences 
in the rate-limiting stimuli that control 
osteogenic-angiogenic coupling in calvar-
ial versus long bone development. For the 
moment, however, the precise reasons for 
the differences observed between long bone 
and calvarial bone formation following Vhl 
deletion remain to be determined.
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Many questions remain to be answered. 
Although HIFα clearly regulates osteo-
genic-angiogenic interactions necessary for 
bone formation, other secreted molecules 
in addition to VEGF, such TNF-α (6, 12, 
13) and FGF2 (5, 27, 28), might contribute 
to this coupling. Potential contributions of 
paracrine TNF-α signaling — an important 
activator of TNFR2-VEGFR2 cross-talk 
(12, 13) and bone formation (6) — have yet 
to be detailed. Should administration of 
bevacizumab, a clinically useful inhibitory 
antibody to VEGF (30), be shown to abro-
gate the bone anabolic effects of osteoblast 
HIFα, this would provide pharmacologic 
evidence that paracrine VEGF signals are 
nonredundant in osteogenic-angiogenic 
coupling. Moreover, since VEGF induces 
the production of bone morphogenetic pro-
tein (BMP) by endothelial cells (5), the con-
sequences of inactivating endothelial BMP 
expression would help support the evolving 
working model (Figure 1). The mechanisms 
that punctuate feed-forward osteogenic-
angiogenic coupling are not known but 
clearly exist, since osteoblast numbers and 
bone formation quickly normalizes postna-
tally at a higher bone mass (3). The “osteo-
stat” mechanism responsible for this physi-
ologic response will be extremely important 
to delineate — and may be metabolically as 
well as mechanically determined. It may 
be possible to selectively augment skeletal 
HIF-1α action — potentially by inhibiting 
specific PHDs — as one strategy to pro-
mote bone formation and fracture healing. 
It will be important to evaluate how the 
material and geometric properties of bone 
manipulated via the HIFα pathway impact 
bone strength. Finally, better markers are 
required to unambiguously characterize 
precursor-product relationships in the 
mesoangioblast/pericyte/osteoblast lin-
eage; such ontogeny is likely to contribute 
to changes in trabecular bone mass depen-
dent upon osteoblast HIFα signaling (16, 
18). All in all, novel and very important bio-
logical principles emerge from the current 
study (3), i.e., that osteogenesis and angio-
genesis are functionally coupled in the mar-
row microenvironment by osteoblast HIFα 
signaling. Thus, in addition to osteoblast 
and osteoclast lineages, the contributions 
of endothelial cell precursors and their 
progeny (Figure 1) must be considered in 
robust studies of bone formation and skel-
etal homeostasis.
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A new study by Galeano and colleagues in this issue of the JCI reports the 
first glomerular disease caused by a genetic defect in sialic acid biosynthe-
sis (see the related article beginning on page 1585). Mice that harbor muta-
tions in the Gne/Mnk gene produce lower amounts of sialic acid, suffer 
from hematuria, proteinuria, and structural defects in the glomerulus and 
die within days after birth. Remarkably, the lesion can be reversed through 
dietary addition of N-acetylmannosamine, a sialic acid precursor, raising the 
intriguing possibility that this approach might have therapeutic benefit in 
patients with glomerular disease.
Nonstandard abbreviations used: Gne, uridine 
diphospho–N-acetylglucosamine 2-epimerase; HIBM, 
hereditary inclusion body myopathy; ManNAc, N-ace-
tylmannosamine; Mnk, ManNAc kinase; PC, podoca-
lyxin; SD, slit diaphragm.
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In this issue of the JCI, Galeano, Huizing, 
and colleagues (1) describe kidney defects in 
knockin mice that harbor the M712T muta-
tion in the gene encoding the key bifunction-
al enzyme of sialic acid biosynthesis — uridine 
diphospho–N-acetylglucosamine 2-epim-
erase/N-acetylmannosamine (ManNAc) 
kinase (GNE/MNK) (GneM712T/M712T mice) 
(2, 3). In patients, mutations in the GNE 
gene result in the autosomal recessive neu-
romuscular disorder, hereditary inclusion 
body myopathy (HIBM; MIM 600737) that 
presents late in life as a slowly progressive 
myopathy (4, 5). The N-acetylglucosamine/
ManNAc enzyme is ubiquitously expressed 
and catalyzes the first rate-limiting steps 
in the biosynthesis of sialic acid (Figure 1). 
5-N-acetylneuraminic acid (Neu5Ac) is the 
most plentiful mammalian sialic acid and 
is the terminal sugar on glycoconjugates, 
where it functions in cellular interactions 
and signaling. Muscle fibers from patients 
with HIBM exhibit reduced sialylation of 
proteins, which is believed to underlie disease 
pathogenesis. Currently, there is no effective 
therapy for this disorder.
In the current study (1), the investiga-
tors sought to develop a mouse model to 
test whether dietary supplementation of 
sialic acid or its precursor, ManNAc, could 
reverse the hyposialylation defect observed 
in patients. Standard Gne knockout mice 
die in utero (6). To overcome this early 
mortality, the authors generated a mouse 
carrying one of the most common non-
lethal mutations observed in patients with 
HIBM. Surprisingly, mice homozygous for 
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